Breaking the Vicious Cycle: New ESC Guidelines for Heart and Kidney Health

The European Society of Cardiology (ESC) has finally put its weight behind a problem that doctors have known for years: heart disease and chronic kidney disease (CKD) feed off each other. In partnership with the European Renal Association, the ESC published a set of recommendations in the European Heart Journal and rolled them out at the ESC Congress 2026.

CKD isn’t just a kidney‑only issue. When the kidneys start to falter—defined as structural or functional abnormalities lasting three months or more—the risk of cardiovascular disease (CVD) skyrockets. Roughly 100 million Europeans live with CKD, and many of them will see a heart problem sooner rather than later.

"The disability and years of life lost to each condition are profound," said task‑force chair Professor Kevin Damman, University Medical Centre Groningen. "What’s encouraging is that a handful of inexpensive, well‑studied treatments can now dramatically cut the risk of both heart attacks and the need for dialysis."

Because the two illnesses often travel together, the new guidelines put a strong emphasis on spotting kidney trouble early in people who are already being treated for CVD. Professor William Herrington of Oxford added, "We need cardiologists to start checking kidney function and urine albumin as part of the routine work‑up. The more we screen, the more we can intervene before things get out of hand."

To make the recommendations easier to remember, the task force coined the acronym STAMP on CKD:

• Screen – Test every cardiovascular patient for kidney disease using a blood‑based eGFR and a urine albumin‑to‑creatinine ratio.
• Triage – Use validated risk scores that incorporate kidney function to gauge the likelihood of progression to dialysis and the imminent cardiovascular threat.
• Address – Start proven, cost‑effective drugs early to slow CKD and lower heart‑event risk.
• Modify – Tailor heart‑specific medications (like certain antiplatelet agents or anticoagulants) when kidney function is reduced.
• Plan – Build coordinated care pathways so cardiologists and nephrologists can act together, and involve patients and families in the decision‑making process.

The "Screen" step is straightforward: a simple blood draw and a spot urine sample. No fancy imaging, no invasive procedures. The eGFR gives a snapshot of how well the kidneys filter waste, while the urine albumin‑to‑creatinine ratio flags early damage that might otherwise be missed.

Once a problem is identified, the "Triage" phase helps clinicians decide who needs urgent attention. The guidelines point to risk calculators that blend traditional cardiovascular scores with kidney metrics, creating a more holistic picture of each patient’s prognosis.

"Early use of RAS inhibitors and SGLT2 inhibitors, together with statins, is a game‑changer," Professor Damman explained. These drug classes have been shown to slow the loss of kidney function and cut heart‑failure hospitalisations, all while being relatively cheap and widely available.

But the guidelines also warn that not every heart drug is safe for a failing kidney. For instance, certain contrast agents or high‑dose ACE inhibitors may need dose‑adjustments or alternatives. The "Modify" component gives concrete advice on when to dial back or switch therapies.

Perhaps the most ambitious part of the new plan is the "Plan" element, which calls for seamless communication between cardiology and nephrology services. Multidisciplinary clinics, shared electronic records, and clear referral pathways are all encouraged. The authors stress that involving patients—and their caregivers—in these conversations leads to better adherence and a more patient‑centred experience.

A simplified, patient‑focused version of the guidelines has also been released. It uses plain language and checklists so anyone can see what tests they should expect and which medicines might be prescribed.

In closing, the task‑force chairs reminded readers that both CVD and CKD are heavy burdens on individuals and health systems alike. By pushing routine kidney screening in cardiac care, and by treating both organs as a linked system rather than isolated targets, the ESC hopes to shrink the twin epidemics and improve quality of life for millions.